A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01499446
First received: December 8, 2011
Last updated: April 11, 2013
Last verified: July 2012
  Purpose

The purpose of this study is to compare the efficacy and safety of GW685698X 100mcg once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening via DISKHALER for 28 days in subjects with persistent bronchial asthma.


Condition Intervention Phase
Asthma
Drug: GW685698X (fluticasone furoate) 100mcg Morning
Drug: GW685698X (fluticasone furoate) 100mcg Evening
Drug: GW685698X (fluticasone furoate) 250mcg Evening
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Double Dummy, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening All Administered by Inhalation Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Peak expiratory flow (PEF) [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning compared with GW685698X 100mcg once daily in the evening by inhalation via DISKHALER.


Secondary Outcome Measures:
  • Peak expiratory flow (PEF) [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 250mcg once daily compared with GW685698X 100mcg once daily both administered in the evening by inhalation via DISKHALER.

  • PEF [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning, 100mcg once daily in the evening, or GW685698X 250mcg once daily in the evening, compared with placebo

  • Clinic lung function [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Change from baseline in pre bronchodilator clinic lung function (forced expiratory volume in 1 second [FEV1] and PEF) after 28 days of treatment with GW685698X 250mcg once daily in the evening compared with GW685698X 100mcg once daily in the evening


Enrollment: 669
Study Start Date: September 2003
Study Completion Date: March 2004
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GW685698X (fluticasone furoate) 100mcg Morning Drug: GW685698X (fluticasone furoate) 100mcg Morning
GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
Experimental: GW685698X (fluticasone furoate) 100mcg Evening Drug: GW685698X (fluticasone furoate) 100mcg Evening
GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
Experimental: GW685698X (fluticasone furoate) 250mcg Evening Drug: GW685698X (fluticasone furoate) 250mcg Evening
GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
Placebo Comparator: Placebo Drug: GW685698X (fluticasone furoate) 100mcg Morning
GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
Drug: GW685698X (fluticasone furoate) 100mcg Evening
GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
Drug: GW685698X (fluticasone furoate) 250mcg Evening
GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
Drug: Placebo
Placebo inhaled twice daily (morning and evening) for 28 days

  Eligibility

Ages Eligible for Study:   16 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Outpatients aged between 16- 65 years.
  • Male and female; female subjects must be non-child bearing potential or of childbearing potenetial with negative pregnancy test and willing to use acceptable contraceptive methods
  • Documented clinical history of persistent asthma first diagnosed at least 6 months prior to Visit 1
  • Currently receiving inhaled short-acting beta-2 agonists for symptom relief
  • A lung function of between 50 to 90% predicted (PEF)
  • Increase in PEF of at least15%, 20 minutes after inhalation of 400mcg salbutamol

Exclusion Criteria:

  • History of respiratory tract infection and/or exacerbation of asthma within a period of 4 weeks prior to Visit 1
  • History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxia seizures.
  • A history of two or more asthma exacerbations requiring treatment with oral corticosteroids or hospitalisation in the 6 months before Visit 1.
  • Past or present disease that, as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematologic disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis and bronchopulmonary dysplasia).
  • Known or suspected sensitivity to corticosteroids, VENTOLIN, or the constituents of ROTADISKS (e.g., lactose).
  • Undergoing allergen desensitisation therapy.
  • Neurological or psychiatric disease or history of drug or alcohol abuse that would interfere with the subject's proper completion of the protocol requirements.
  • Is a current smoker or has a smoking history of 10 pack years or more (e.g., 20 cigarettes/day for 10 years). Note: Current smoker is defined as currently smoking or stopped smoking within 6 months of screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01499446

Locations
Estonia
GSK Investigational Site
Kohtal-Jdrve, Estonia, 31 025
GSK Investigational Site
Tallinn, Estonia, 1162
GSK Investigational Site
Tartu, Estonia, 51014
Germany
GSK Investigational Site
Eschwege, Hessen, Germany, 37269
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30167
GSK Investigational Site
Lueneburg, Niedersachsen, Germany, 21335
GSK Investigational Site
Geesthacht, Schleswig-Holstein, Germany, 21502
GSK Investigational Site
Berlin, Germany, 10969
Greece
GSK Investigational Site
Athens, Greece, 115 28
GSK Investigational Site
Athens, Greece, 15669
GSK Investigational Site
Papagos/Athens, Greece, 15669
Hungary
GSK Investigational Site
Törökbálint, Hungary, 2045
Mexico
GSK Investigational Site
Mexico, D.F., Mexico, 06720
Romania
GSK Investigational Site
Brasov, Romania
GSK Investigational Site
Bucharest, Romania, 050159
GSK Investigational Site
Bucuresti, Romania, 70000
Russian Federation
GSK Investigational Site
Kazan, Russian Federation, 420015
GSK Investigational Site
Moscow, Russian Federation, 115446
GSK Investigational Site
Moscow, Russian Federation, 123 182
GSK Investigational Site
Moscow, Russian Federation, 115478
GSK Investigational Site
St. Petersburg, Russian Federation, 197 089
GSK Investigational Site
St. Petersburg, Russian Federation, 197022
GSK Investigational Site
Tomsk, Russian Federation, 634 050
GSK Investigational Site
Volgograd, Russian Federation, 400130
South Africa
GSK Investigational Site
Bloemfontein, South Africa, 9300
GSK Investigational Site
Cape Town, South Africa, 7500
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01499446     History of Changes
Other Study ID Numbers: FFA20001
Study First Received: December 8, 2011
Last Updated: April 11, 2013
Health Authority: Mexico: Ethics Committee
Bulgaria: LEC
Russia: Ethics Committee
Romania: Agentia Nationala a Medicamentului
Italy: Ethics Committee
Estonia: ERC on Human Research of the University of Tartu
Romania: Minister of Health
Chile: Comite de Etica Cientifica Servicio de Salud Metropolitano Oriente
Croatia: Ministry of health and Social Welfare
Germany: Berlin Ethics Committee
Greece: National Drug Organisation

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 18, 2014